IL-4 blockade also alters inflammation in the tumour microenvironment, reducing the generation of both immunosuppressive M2 macrophages and myeloid-derived suppressor cells and enhancing tumour-specific cytotoxic T lymphocytes [24]. Here, IL4 is linked to neoplasm.